Stem Point Capital LP Neurocrine Biosciences Inc Call Options Transaction History
Stem Point Capital LP
- $314 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
652Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.72 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.2 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$670 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$588 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$323 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...